Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities
Net loss	$ (59,719)	$ (83,955)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash other expense, net	(49)	167
Non-cash interest income	24	(57)
Non-cash interest expense	379
Depreciation and amortization expense	162	391
Amortization of right-of-use assets	291
Stock-based compensation	7,866	3,434
In-process research and development in connection with acquisition		31,930
Deferred income taxes	(5)
Other, net		12
Changes in operating assets and liabilities:
(Increase)/decrease in long-term receivables	(288)	(3)
(Increase)/decrease in accounts receivable, net and other receivables and prepaid expenses	(1,258)	(2,361)
Increase in inventory	(162)
(Decrease)/increase in accounts payable	(39)	(1,473)
Increase/(decrease) in accrued expenses and other liabilities	(3,553)	1,137
Increase/(decrease) in other non-current liabilities	(88)	41
Increase/(decrease) in income tax liabilities	34	245
Net cash used in operating activities	(56,405)	(50,492)
Cash flows from investing activities
Purchases of plant and equipment and intangible assets	(97)	(209)
Purchases of term deposits		(216)
Deposits into employee stock purchase plan restricted cash accounts	228
Transaction costs related to Zavante acquisition, net of cash acquired		(3,950)
Net cash provided by (used in) investing activities	131	(4,375)
Cash flows from financing activities
Proceeds from at-the-market facility	23,189	22,784
Proceeds from long-term debt, net of issuance costs	9,980	535
Proceeds from employee share purchase plan	170
Equity transaction costs	(659)	(4,723)
Net cash provided by financing activities	32,680	68,596
Effects of foreign currency translation on cash and cash equivalents	(80)	(167)
Net increase/(decrease) in cash, cash equivalents and restricted cash	(23,674)	13,562
Cash, cash equivalents and restricted cash at beginning of period	102,003	86,769
Cash, cash equivalents and restricted cash at end of period	78,329	100,331
Supplemental disclosure of cash flow information:
Transaction costs related to Zavante acquisition included in accounts payable and accrued expensed		243
Interest paid	1,735	4
Equity transaction costs incurred in prior periods and paid in current period	18
Equity transaction costs included in accounts payable and accrued expenses	$ 382	109
July 2018 Public Offering
Cash flows from financing activities
Proceeds from at-the-market facility		$ 50,000